Attana receives contract research order from a global pharma company

Attana has received ontract research order from an global pharma company with headquarter in Europe. The contract is the results of the previous performed experiments for the pharma company, but from a new orginisational unit and within a different area. The experiments are based on Attana’s patented biosensor and will included detailed interaction charaterization of the drug molecule.

Attana’s application specialists will perform experiments where different interactions at different conditions will be studied. It is a smaller contract, but with a potential for further contract later on.

For more information, please contact:

Teodor Aastrup, CEO Attana AB
e-mail: teodor.aastrup@attana.com 
tel: + 46 8 674 57 00

The Board of directors for Attana consider that the information in this press release is not likely to have a significant effect on the share prices, but is of general interest for the shareholders and hence should be communicated.

Attana was founded in 2002 with the vision of in-vitro characterization of molecular interactions mimicking in-vivo conditions. Since then, Attana has developed proprietary label free biosensors for biochemical, crude, sera, and cell-based assays. Attana’s products and research services are used by Big Pharma, biotech companies and academic institutions within the life sciences. To learn more about Attana’s contract research services and our label free cell-based biosensors, please visit www.attana.com or contact  sales@attana.com. 

Tags: